A. Wallace

W. Newman, C. Dive, F. Blackhall, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Combining evidence for and against pathogenicity for variants in cancer susceptibility genes: CanVIG-UK consensus recommendations

S. Ellard, D. Eccles, C. Turnbull, 2020, Journal of Medical Genetics.

Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England

G. Jayson, D. Evans, E. Harkness, 2020, European Journal of Human Genetics.

Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases

G. Jayson, D. Evans, G. Burghel, 2019, Journal of Medical Genetics.

Early Adaptation of Colorectal Cancer Cells to the Peritoneal Cavity Is Associated with Activation of “Stemness” Programs and Local Inflammation

R. Bristow, D. Evans, C. Dive, 2020, Clinical Cancer Research.

Use of MRI and audiological tests in presymptomatic diagnosis of type 2 neurofibromatosis (NF2)

D. Evans, R. Macleod, J. Jenkins, 2000, Journal of medical genetics.

Intrafamilial correlation of clinical manifestations in neurofibromatosis 2 (NF2)

Yinshan Zhao, G. Rouleau, G. Rouleau, 2002, Genetic epidemiology.

The utility of TP53 and PIK3CA mutations as prognostic biomarkers in salivary adenoid cystic carcinoma.

K. Harrington, G. Betts, R. Metcalf, 2020, Oral oncology.

A Dominantly Inherited 5′ UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer

Javier Santoyo-Lopez, D. Eccles, W. Newman, 2018, American journal of human genetics.

Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention

J. Waller, A. Antoniou, I. Jacobs, 2020, Cancers.

Variation in pre-PCR processing of FFPE samples leads to discrepancies in BRAF and EGFR mutation detection: a diagnostic RING trial

Marilyn M. Li, Joshua L. Deignan, R. Butler, 2014, Journal of Clinical Pathology.

Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing

D. Evans, D. Halliday, M. Kellett, 2018, Genetics in Medicine.

30 year experience of index case identification and outcomes of cascade testing in high-risk breast and colorectal cancer predisposition genes

D. Evans, F. Lalloo, T. Clancy, 2021, European Journal of Human Genetics.

Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families

A. Shenton, F. Lalloo, A. Wallace, 2008, Clinical genetics.

Multiple Meningiomas as a Criterion for the Diagnosis of Neurofibromatosis Type 2 and Other Tumor Predisposition Syndromes

S. Rutherford, A. Wallace, S. Lloyd, 2022, Neurosurgery.

Clinical and molecular correlates of somatic mosaicism in neurofibromatosis 2

D. Evans, T. Strachan, M. Baser, 2000, Journal of medical genetics.

Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas

D. Evans, A. Read, R. Ramsden, 2002, Journal of medical genetics.

The Contribution of Whole Gene Deletions and Large Rearrangements to the Mutation Spectrum in Inherited Tumor Predisposing Syndromes

E. Harkness, E. Miles, A. Wallace, 2016, Human mutation.

Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma

R T Ramsden, D. Evans, T. Strachan, 1999, Journal of neurology, neurosurgery, and psychiatry.

Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring

S. Purcell, D. Evans, R. Ramsden, 2003, Journal of medical genetics.

Bilateral vestibular schwannomas in older patients: NF2 or chance?

D. Evans, S. Huson, R. Ramsden, 2015, Journal of Medical Genetics.

Mutation type and position varies between mosaic and inherited NF2 and correlates with disease severity

A. Wallace, N. Bowers, S. Huson, 2013, Clinical genetics.

An update on age related mosaic and offspring risk in neurofibromatosis 2 (NF2)

D. Evans, A. Wallace, 2009, Journal of Medical Genetics.

Practice guidelines for Sanger Sequencing Analysis and Interpretation.

S. Ellard, G. Taylor, S. Ramsden, 2009 .

Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation

D. Evans, J. Varley, R. Ramsden, 2003, Journal of medical genetics.

Re‐evaluation of missense variant classifications in NF2

L. Messiaen, A. Wallace, N. Roberts, 2022, Human mutation.

Advances in genetic technologies result in improved diagnosis of mismatch repair deficiency in colorectal and endometrial cancers

D. Evans, F. Lalloo, T. Clancy, 2021, Journal of Medical Genetics.

The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study

D. Evans, I. Frayling, E. Crosbie, 2020, PLoS medicine.

Semiquantitative assessment of immunohistochemistry for mismatch repair proteins in Lynch syndrome

G. Evans, A. Wallace, R. McMahon, 2010, Histopathology.

Inherited BRCA1 epimutation as a novel cause of breast and ovarian cancer

Javier Santoyo-Lopez, D. Eccles, D. Evans, 2018, bioRxiv.

Mutation scanning of the NF2 gene: an improved service based on meta-PCR/sequencing, dosage analysis, and loss of heterozygosity analysis.

D. Evans, A. Wallace, R. Elles, 2004, Genetic testing.

Frequency of SMARCB1 mutations in familial and sporadic schwannomatosis

D. Evans, R. Ferner, G. Leschziner, 2012, neurogenetics.

Confirmation that somatic mutations of beta‐2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial

D. Evans, P. Quirke, S. Richman, 2019, Histopathology.

Genotype-phenotype correlations for cataracts in neurofibromatosis 2

D. Evans, R. Ramsden, M. Baser, 2003, Journal of medical genetics.

SSCP/heteroduplex analysis.

A. Wallace, 2002, Methods in molecular biology.

A deep intronic SMARCB1 variant associated with schwannomatosis

S. Bhaskar, Meredith Wilson, A. Wallace, 2020, Clinical genetics.

Validation of ROS1 by immunohistochemistry against fluorescent in situ hybridisation on cytology and small biopsy samples in a large teaching hospital

D. Rana, F. Blackhall, C. Lindsay, 2021, Cytopathology : official journal of the British Society for Clinical Cytology.

Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study

Crispin J. Miller, S. Gulati, R. Marais, 2019, Nature Medicine.

The TARGET trial: Molecular profiling of circulating tumour DNA to stratify patients to early phase clinical trials

Crispin J. Miller, S. Gulati, R. Marais, 2016 .

Sarcoma in neurofibromatosis 2: case report and review of the literature

D. Evans, A. Freemont, A. Wallace, 2018, Familial Cancer.

Cystic fibrosis mutation analysis: Report from 22 U.K. regional genetics laboratories

M. Tassabehji, D. Barton, G. Taylor, 1995, Human mutation.

Meta-PCR: a novel method for creating chimeric DNA molecules and increasing the productivity of mutation scanning techniques.

A. Wallace, R. Elles, C. L. Wu, 1999, Genetic testing.

Semi-automated unidirectional sequence analysis for mutation detection in a clinical diagnostic setting.

B. Shields, S. Ellard, C. Mattocks, 2009, Genetic testing and molecular biomarkers.

Sarcoma in neurofibromatosis 2

A. Freemont, M. Kalamarides, A. Wallace, 2017 .

Mutation Scanning for the Clinical Laboratory

A. Wallace, 2004 .

Mutation scanning for the clinical laboratory: automated fluorescent sequencing.

A. Wallace, 2004, Methods in molecular medicine.

Semiquantitative assessment of immunohistochemistry for mismatch repair proteins in Lynch syndrome

G. Evans, A. Wallace, R. McMahon, 2010, Histopathology.

The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2

C. Lázaro, G. Rouleau, R. Ramsden, 2005, Journal of Medical Genetics.